Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) had a rough 2011. If the pre-market trading indications manage to last throughout the day, then it appears that Teva could be off to a great start in 2012. The company just announced that it will have a new Chief Executive Officer. Whether you look at Teva for its generic gains or its branded products, this may matter. The company’s current CEO will retire in May and will be replaced by Jeremy Levin upon retirement. Teva was well above $50 throughout much of early 2011 and ended up going under $40.00 before recovering. Shares closed out at $40.36 on Friday and the stock is indicated up 3.6% at $41.82 so far this Tuesday morning to start of 2012.
JON C. OGG
Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
